Among these were three variants with a high likelihood of germline origin, independent of VAF [40], identified in two patients who passed away before undergoing GGT: a BRCA1 TGV (VAF 37%) in a bladder cancer, and a BRCA2 TGV (VAF 14%) along with the HOXB13 G84E founder mutation (VAF 53%) in a porocarcinoma. Here, HOXB13 is linked to urinary bladder carcinoma.